Stage I Marginal Zone Lymphoma Completed Phase 1 Trials for Rituximab (DB00073)

IndicationStatusPhase
DBCOND0029479 (Stage I Marginal Zone Lymphoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00058227Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell LymphomaTreatment